Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: Real-life data from a swiss cohort

Clinical Neuropharmacology

Volumn 35, Issue 2, 2012, Pages 77-80

  Kallweit, Ulf ^a   Jelcic, Ilijas ^a   Braun, Nathalie ^a   Fischer, Heike ^a   Zörner, Björn ^a   Schreiner, Bettina ^a   Sokolov, Arseny A ^a   Martin, Roland ^a   Weller, Michael ^a   Linnebank, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

annual relapse rate; EDSS; multiple sclerosis; natalizumab; real life

Indexed keywords

NATALIZUMAB;

ADULT; AGED; ARTICLE; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; SWITZERLAND;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DATABASES, FACTUAL; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SWITZERLAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863419784     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824644e6     Document Type: Article

References (12)

1. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;3:254-260.
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
3. Prosperini L, Borriello G, Fubelli F, et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 2011;31(suppl 3):303-307.
4. Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009;16:420-423.
5. Putzki N, Yaldizli O, Buhler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010;63:101-106.
6. Memon A, Caon C, Perumal J, et al. Natalizumab is effective in RRMS patients who do not respond to sequential therapy with interferon beta and glatiramer acetate: results of a switching study. Neurology 2010;74:A542.
7. Fernandez O, Alvarenga MP, Guerrero M, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler 2011;17:192-197.
8. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 2010;17:490-494.
9. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing-multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)
10. Holmén C, Piehl F, Hillert J, et al. Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011;17(6):708-719.
11. Polman C, Reingold S, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846. (Pubitemid 41746873)
12. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.